Melatonin alleviates lipopolysaccharide-induced hepatic SREBP-1c activation and lipid accumulation in mice

Journal of Pineal Research

Volumn 51, Issue 4, 2011, Pages 416-425

  Chen, Xi ^a   Zhang, Cheng ^a   Zhao, Mei ^a   Shi, Chang E ^a   Zhu, Ren Min ^a   Wang, Hua ^a   Zhao, Hui ^a   Wei, Wei ^a   Li, Jia Bin ^a   Xu, De Xiang ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

lipopolysaccharide; melatonin; nonalcoholic fatty liver disease; sterol regulatory element binding protein

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; FATTY ACID SYNTHASE; LIPOPOLYSACCHARIDE; MELATONIN; REACTIVE OXYGEN METABOLITE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTOXEMIA; ENZYME ANALYSIS; LIPID ANALYSIS; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN DETERMINATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 80054801450     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2011.00905.x     Document Type: Article

References (55)

1. Fan JG, Farrell GC,. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009; 50: 204-210.
2. Fabbrini E, Sullivan S, Klein S,. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010; 51: 679-689.
3. Farrell GC, Larter CZ,. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112.
4. Postic C, Girard J,. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008; 118: 829-838. (Pubitemid 351364588)
5. Zhao L, Chen YH, Wang H, et al., Reactive oxygen species contribute to lipopolysaccharide-induced teratogenesis in mice. Toxicol Sci 2008; 103: 149-157. (Pubitemid 351524486)
6. Cani PD, Amar J, Iglesias MA, et al., Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-1772. (Pubitemid 47025442)
7. Erridge C, Attina T, Spickett CM, et al., A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007; 86: 1286-1292. (Pubitemid 350126229)
8. Cani PD, Bibiloni R, Knauf C, et al., Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57: 1470-1481.
9. Thuy S, Ladurner R, Volynets V, et al., Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008; 138: 1452-1455.
10. Harte AL, Da Silva NF, Creely SJ, et al., Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond) 2010; 7: 15.
11. Bergheim I, Weber S, Vos M, et al., Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008; 48: 983-992.
12. Endo M, Masaki T, Seike M, et al., TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Exp Biol Med (Maywood) 2007; 232: 614-621. (Pubitemid 46683386)
13. Laurent A, Nicco C, Tran Van Nhieu J, et al., Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis. Hepatology 2004; 39: 1277-1285. (Pubitemid 38569049)
14. Wei Y, Clark SE, Morris EM, et al., Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol 2008; 49: 417-428.
15. Musso G, Gambino R, Cassader M,. Redox Balance in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Opportunities. Antioxid Redox Signal. 2011; doi:.
16. Tan DX, Chen LD, Poeggeler B, et al., Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocrine J 1993; 1: 57-60.
17. Tan DX, Manchester LC, Terron MP, et al., One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007; 42: 28-42. (Pubitemid 44924323)
18. Hardeland R, Tan DX, Reiter RJ,. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 2009; 47: 109-126.
19. Schaefer M, Hardeland R,. The melatonin metabolite N-acetyl-5- methoxykynuramine is a potent singlet oxygen scavenger. J Pineal Res 2009; 46: 49-52.
20. Barlow-Walden LR, Reiter RJ, Abe M, et al., Melatonin stimulates brain glutathione peroxidase activity. Neurochem Int 1995; 26: 497-502.
21. Pablos MI, Agapito MT, Gutierrez R, et al., Melatonin stimulates the activity of the detoxifying enzyme glutathione peroxidase in several tissues of chicks. J Pineal Res 1995; 19: 111-115.
22. Rodriguez C, Mayo JC, Sainz RM, et al., Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36: 1-9. (Pubitemid 38130283)
23. Tomas-Zapico C, Coto-Montes A,. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J Pineal Res 2005; 39: 99-104. (Pubitemid 41140746)
24. Xu DX, Wang H, Ning H, et al., Maternally administered melatonin differentially regulates lipopolysaccharide-induced proinflammatory and anti-inflammatory cytokines in maternal serum, amniotic fluid, fetal liver, and fetal brain. J Pineal Res 2007; 43: 74-79. (Pubitemid 47035224)
25. Chahbouni M, Escames G, Venegas C, et al., Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. J Pineal Res 2010; 48: 282-289.
26. Gilad E, Wong HR, Zingarelli B, et al., Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFkappaB activation. FASEB J 1998; 12: 685-693. (Pubitemid 28247147)
27. Crespo E, Macias M, Pozo D, et al., Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats. FASEB J 1999; 13: 1537-1546. (Pubitemid 29411787)
28. Escames G, Acuna-Castroviejo D, Lopez LC, et al., Pharmacological utility of melatonin in the treatment of septic shock: experimental and clinical evidence. J Pharm Pharmacol 2006; 58: 1153-1165. (Pubitemid 44335028)
29. Wu CC, Chiao CW, Hsiao G, et al., Melatonin prevents endotoxin-induced circulatory failure in rats. J Pineal Res 2001; 30: 147-156. (Pubitemid 32245285)
30. Schaffer JE,. Fatty acid transport: the roads taken. Am J Physiol Endocrinol Metab 2002; 282: E239-E246. (Pubitemid 34654793)
31. Gobin S, Thuillier L, Jogl G, et al., Functional and structural basis of carnitine palmitoyltransferase 1A deficiency. J Biol Chem 2003; 278: 50428-50434. (Pubitemid 37548887)
32. Pan M, Song YL, Xu JM, et al., Melatonin ameliorates nonalcoholic fatty liver induced by high-fat diet in rats. J Pineal Res 2006; 41: 79-84. (Pubitemid 43980699)
33. Tahan V, Atug O, Akin H, et al., Melatonin ameliorates methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis in rats. J Pineal Res 2009; 46: 401-407.
34. Mao J, Demayo FJ, Li H, et al., Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis. Proc Natl Acad Sci U S A 2006; 103: 8552-8557. (Pubitemid 43838493)
35. Xu A, Wang Y, Keshaw H, et al., The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100. (Pubitemid 38056380)
36. Uyeda K, Repa JJ,. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab 2006; 4: 107-110. (Pubitemid 44138720)
37. Dentin R, Benhamed F, Hainault I, et al., Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes 2006; 55: 2159-2170. (Pubitemid 44743612)
38. Shimomura I, Bashmakov Y, Horton JD,. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 1999; 274: 30028-30032.
39. Sekiya M, Yahagi N, Matsuzaka T, et al., Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003; 38: 1529-1539. (Pubitemid 37466979)
40. Kammoun HL, Chabanon H, Hainault I, et al., GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest 2009; 119: 1201-1215.
41. Aragno M, Tomasinelli CE, Vercellinatto I, et al., SREBP-1c in nonalcoholic fatty liver disease induced by Western-type high-fat diet plus fructose in rats. Free Radic Biol Med 2009; 47: 1067-1074.
42. Kim YW, Kim YM, Yang YM, et al., Inhibition of SREBP-1c-mediated hepatic steatosis and oxidative stress by sauchinone, an AMPK-activating lignan in Saururus chinensis. Free Radic Biol Med 2010; 48: 567-578.
43. Lawler JF Jr, Yin M, Diehl AM, et al., Tumor necrosis factor-alpha stimulates the maturation of sterol regulatory element binding protein-1 in human hepatocytes through the action of neutral sphingomyelinase. J Biol Chem 1998; 273: 5053-5059. (Pubitemid 28108663)
44. Carrillo-Vico A, Lardone PJ, Naji L, et al., Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: regulation of pro-/anti-inflammatory cytokine network, protection against oxidative damage and anti-apoptotic effects. J Pineal Res 2005; 39: 400-408.
45. Xu DX, Wei W, Sun MF, et al., Melatonin attenuates lipopolysaccharide- induced down-regulation of pregnane X receptor and its target gene CYP3A in mouse liver. J Pineal Res 2005; 38: 27-34. (Pubitemid 40139307)
46. Yoshikawa T, Shimano H, Amemiya-Kudo M, et al., Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol Cell Biol 2001; 21: 2991-3000. (Pubitemid 32298367)
47. Joseph SB, Laffitte BA, Patel PH, et al., Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem 2002; 277: 11019-11025. (Pubitemid 34952859)
48. Myhre AE, Agren J, Dahle MK, et al., Liver X receptor is a key regulator of cytokine release in human monocytes. Shock 2008; 29: 468-474. (Pubitemid 351416800)
49. Wang YY, Dahle MK, Agren J, et al., Activation of the liver X receptor protects against hepatic injury in endotoxemia by suppressing Kupffer cell activation. Shock 2006; 25: 141-146.
50. Reddy JK, Rao MS,. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 2006; 290: G852-G858.
51. Patsouris D, Reddy JK, Muller M, et al., Peroxisome proliferator- activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology 2006; 147: 1508-1516. (Pubitemid 43244386)
52. Zhou J, Zhai Y, Mu Y, et al., A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J Biol Chem 2006; 281: 15013-15020. (Pubitemid 43855205)
53. Zhou J, Febbraio M, Wada T, et al., Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 2008; 134: 556-567.
54. Beigneux AP, Moser AH, Shigenaga JK, et al., The acute phase response is associated with retinoid X receptor repression in rodent liver. J Biol Chem 2000; 275: 16390-16399. (Pubitemid 30366957)
55. Xu DX, Wei W, Sun MF, et al., Kupffer cells and reactive oxygen species partially mediate lipopolysaccharide-induced downregulation of nuclear receptor pregnane x receptor and its target gene CYP3a in mouse liver. Free Radic Biol Med 2004; 37: 10-22. (Pubitemid 38746647)